D.J.M.). The online-only Data Supplement is available with this article at http://circres.ahajournals.org/lookup/suppl/is prominently expressed in arterial smooth muscle cells. Our group first reported that RGS5 is important in vascular remodeling during tumor angiogenesis. We hypothesized that RGS5 may play an important role in vessel wall remodeling and blood pressure regulation.
B lood vessels consist of 2 major cell types, endothelial and mural cells, such as pericytes and vascular smooth muscle cells (VSMC), which surround the endothelium. Regulator of G-protein signaling 5 (RGS5) is expressed in mural cells and has emerged as a crucial modulator of vascular pathology in cancer. For instance, we have demonstrated that RGS5 is highly upregulated in angiogenic tumor pericytes. 1 Loss of RGS5 results in pericyte maturation and normalization of tumor vasculature. 2, 3 Moreover, we showed a crucial role for RGS5 in regulating vascular barrier function in tumors and in brain capillaries during ischemia, and also provided the first genetic evidence that RGS5 is involved in vascular wall remodeling in adults. 2 A striking feature of RGS5 expression is its dynamic nature in various physiological and pathological states, which indicates a role in adaptive processes. 1, [4] [5] [6] This is consistent with RGS5 being a member of the extended family of RGS molecules, which are modulators of G-protein-coupled receptors (GPCRs). G-protein signaling pathways rely on rapid on-off kinetics, and RGS molecules act as GTPaseactivating proteins (GAP) for heterotrimeric G proteins and, as such, regulate duration and intensity of signaling events. They contain a highly conserved carboxyl-terminal RGS domain that confers the catalytic function for active Gα subunits. Members of the R4/B subfamily, which include, among others, RGS 2, 4, and 5, are the smallest RGS proteins and contain only short peptide sequences flanking the RGS box. Nevertheless, there is increasing evidence that RGS molecules interact with other cellular proteins downstream of GPCRs and exert effects beyond their GAP activity. 7 Importantly, recent data from transgenic and knockout (KO) mice highlight a critical role for some RGS molecules in cardiovascular function. 8, 9 For instance, RGS2deficient mice develop hypertension and consequent cardiac hypertrophy. 10, 11 Conversely, cardiac-specific RGS4 or RGS5 overexpression in transgenic mice has a protective effect in late-stage heart failure by counter-regulating hypertrophic stimuli 12 or preventing hypertrophy in response to pressure overload, respectively. 13 So far, RGS5 has been shown to accelerate GTP hydrolysis of Gα i and Gα q in vitro and to attenuate the mitogenactivated protein kinase pathway. [13] [14] [15] Interestingly, RGS5 is overexpressed in arteries compared with veins, 16 and its expression dynamically changes after aortic banding. 6 This indicates that RGS5 may regulate hemodynamic adaptation in arteries. Furthermore, RGS5 is downregulated in arteries from hypertensive rats, which implies a more direct involvement in regulation of vascular tone. 17 In humans, RGS5 gene polymorphism has been associated with hypertension. [18] [19] [20] In earlier studies, RGS5-deficient mice have been shown to be hypotensive relative to wild-type (WT) controls. 21, 22 This remains an unexpected finding and difficult to reconcile with our current understanding of the function of RGS5 as a negative regulator of vasoconstriction. 8, 9 Here, we demonstrate that loss of RGS5 results in hypertension, a finding that is supported by complementary functional assays. This establishes a nonredundant crucial role for RGS5 in vascular function and blood pressure homeostasis.
Methods
Detailed methods are provided in the Online Data Supplement. Hemodynamic measurements in conscious mice were conducted with telemetry probes (Data Sciences International). For blood pressure measurement in anesthetized mice, a Millar 1.4-F probe and transducer (ADInstruments) were used. Blood flow in femoral arteries was assessed with a transit-time ultrasonic system (Transonic Systems). Angiotensin II (AngII) infusion (Alzet) and abdominal aortic constriction (modified 2-kidney 1-clip [2K1C]) were used to generate hypertension. Femoral VSMC were isolated, and cytosolic calcium was monitored using the fluorescent indicator Fura-2 AM. In-cell Western assays were performed using the Odyssey Infrared Imaging System (LI-COR Biosciences).
Results

RGS5 Levels Are Reduced With Chronically Elevated Blood Pressure
The vasoactive peptide of the renin-angiotensin system, AngII, and its GPCRs play a major role in cardiovascular regulation and the pathogenesis of hypertension. To test the hypothesis that RGS5 levels change during vessel wall remodeling, WT mice were infused with AngII (1 mg/kg per day) for 21 days. As expected, this treatment resulted in a slow rise of MAP with a 38% increase at end point (untreated 82.7±2.8 vs treated 113.9±2.6 mm Hg; Figure 1 ). For the first 2 days after minipump implantation, aortic RGS5 expression and blood pressure remained unchanged. From day 2 onward, however, RGS5 levels were significantly reduced and further decreased over time. Interestingly, a decline in RGS5 levels preceded changes in blood pressure, which became apparent on day 7. Reduced RGS5 expression also was observed in a physiological model of renin-angiotensin-mediated hypertension (modified 2K1C) 23 but not after L-NAME (Nω-nitrol-arginine methyl ester) infusion (Online Figure I) . Thus, arterial RGS5 levels inversely correlated with changes in blood pressure in AngII-mediated hypertension. We hypothesized that under physiological conditions, RGS5 provides negative feedback to AngII signaling. However, under chronic conditions, for instance, excessive or prolonged AngII signaling, loss of RGS5 results in pathologically high blood pressure.
RGS5 Controls Blood Pressure
To investigate whether RGS5 is causally involved in blood pressure regulation, RGS5-deficient mice 2 Wild-type mice were left untreated (control) or implanted with angiotensin II (AngII)-releasing minipumps (Alzet, 1 mg/kg per day) for 6 hours and 1, 2, 7, and 21 days. Mean arterial blood pressure (MAP) was assessed in anesthetized mice (n=6); ***P≤0.001 AngII vs untreated). Aortas were harvested, and RGS5 mRNA expression was analyzed using quantitative polymerase chain reaction (n=4-6), *P=0.04 control vs day 2 AngII; **P=0.03 control vs day 7 AngII; ***P≤0.001 control vs day 21 AngII (t test).
with radiotelemetry devices and diurnal variations in blood pressure, heart rate, and locomotor activity measured over 72 hours. MAP in RGS5 KO mice is significantly higher than in WT controls during the day (WT 83.3±2.6 vs KO 115.3±5.1 mm Hg; ΔMAP, 32 mm Hg; P≤0.0001). Murine blood pressure shows circadian variations and increases at night when mice become active. Interestingly, KO mice showed a significantly higher nocturnal blood pressure increase over WT mice (WT 102.0±2.5 vs KO 150.7±4.4 mm Hg; ΔMAP, 48.6 mm Hg; P≤0.0001), even though locomotor activity did not differ between groups (Figure 2A and Online Figure  II) . Heart rates are also identical between experimental groups (Online Figure II ). Similar differences in MAP were recorded for both male and female RGS5 KO mice on 2 different genetic backgrounds (C3H and C57BL/6), whereas heterozygote deletion of RGS5 did not result in hypertension (Online Figure II) . Moreover, acute treatment of RGS5-deficient mice with an AngII receptor 1 (ATR1) antagonist normalizes blood pressure, demonstrating that signaling through ATR1 is a major effector mechanism in RGS5-mediated hypertension ( Figure 2B ). We also found that chronic infusion of AngII (1 mg/kg per day) for 21 days increased blood pressure more profoundly in RGS5deficient mice than in WT controls (ΔMAP WT 29.2±2.1 vs KO 51.4±3.1 mm Hg; Figure 2C and 2D; P≤0.0001), thus supporting a role for RGS5 within the renin-angiotensin signaling pathway. Loss of 1 RGS5 allele in heterozygote RGS5 mice is sufficient to increase blood pressure above that of WT mice under chronic AngII infusion. ATR1 receptor levels are unchanged in RGS5 KO mice, which supports a postreceptor regulatory mechanism (Online Figure II) . Also, RGS2 and RGS4 expressions are unchanged in unchallenged RGS5 KO mice. Under AngII infusion, RGS2 is significantly upregulated in RGS5-deficient mice (Online Figure II; P=0.04). Nevertheless, loss of RGS5 is sufficient to cause hypertension and may result in hyper-responsiveness to vasoconstrictor-mediated responses. This finding is consistent with a critical role of RGS5 in terminating vasoconstrictor-mediated GPCR signaling. 24
RGS5 Regulates Vascular Flow and Contractility
AngII-mediated blood pressure control is complex and involves multiple organs, including brain, kidney, and the vascular wall. Circulating aldosterone and renin concentrations in RGS5 KO and WT mice are not significantly altered (Online Table I ). Given the important role of RGS5 in angiogenic vessel remodeling, we hypothesized that RGS5 directly modulates vascular tone. To address this, hindlimb blood flow was measured by an ultrasonic transit-time flow probe. Acute injection of the vasoconstrictor AngII reduces femoral artery blood flow in RGS5 KO mice more profoundly than in WT controls ( Figure 3A ). These findings imply that RGS5 directly regulates vascular resistance, most likely by affecting vessel contractions. Significantly enhanced contraction in response to AngII was measured in mesenteric vessels from RGS5 KO mice ( Figure 3B ; P=0.0009). Enhanced vessel conductance and contractility also were observed with phenylephrin stimulation but not with endothelin or ATP (Online Figure III) , indicating selectivity of RGS5-regulated effects in these vascular beds. Vessel contractility is, in part, mediated by alterations in cytosolic-free calcium (Ca 2+ ) concentrations. To assess the role of RGS5 in pressor-induced calcium release, Fura-2-loaded VSMC derived from femoral arteries of WT and RGS5 KO mice were stimulated with AngII in a dosedependent manner. Before stimulation with AngII, there was no difference in basal calcium levels in VSMC from WT and KO mice (Online Figure IV) . Addition of AngII, A, Wild-type (WT) and RGS5 KO mice were implanted with radiotelemetry devices and mean arterial pressure (MAP)/ activity recorded over 72 h (n=8-12) (*P≤0.0001). Average MAP values for 3 consecutive days and nights are shown (*P≤0.0001). Systolic/diastolic blood pressures are shown in Online Figure II . B, WT and KO mice with telemetry implants were acutely treated with angiotensin II (AngII) receptor 1 (ATR1) antagonist (20 mg/ kg) and MAP was recorded for 2 hours (n=6) (*P≤0.001). C, WT, heterozygote RGS5 knockout (HET), and KO mice were implanted with telemetry devices. After a recovery period of 10 days (day 0), baseline MAP was recorded for 30 minutes per day for 3 days. On day 4, AngII pumps were implanted intraperitoneally (1 mg/kg per day) and blood pressure was recorded daily for 30 minutes (n=3-4) (*P≤0.0001). D, Difference between baseline blood pressure and maximal blood pressure (*P≤0.0001).
however, increased Fura-2 340/380 nm fluorescence in RGS5-deficient VSMC by 25% ( Figure 3C ). These findings establish a direct link between RGS5 expression and Ca 2+dependent vessel contraction, vascular resistance, and hypertension. Because vascular contractility and vessel wall remodeling are crucial in the development of hypertension, we hypothesized that chronic vasoconstriction in the absence of RGS5 also may cause structural alterations A Angll Angll A, Anesthetized wild-type (WT) and RGS5 knockout (KO) mice were acutely injected with increasing doses of angiotensin II (AngII). Mean arterial pressure (MAP) and blood flow in femoral arteries were measured to calculate vessel conductance (n=6; *P≤0.0001). B, Mesenteric arteries were mounted on a wire myograph and exposed to increasing concentrations of AngII. in the vessel wall. To assess the passive mechanical wall properties, stress-strain relationships for arteries from 6-week-old WT and KO mice were determined. The stressstrain relationship for femoral arteries from RGS5 KO mice is significantly shifted to the left compared with WT ( Figure  3D ; P=0.01), indicating that femoral arteries of RGS5 KO mice are stiffer. This may facilitate the hypertensive phenotype, which is largely controlled by enhanced smooth muscle contractility.
Age-Dependent Vascular Stiffening in RGS5-Deficient Mice
To assess the impact of RGS5 deficiency over time, blood pressure in young (6 weeks Figure V) , mesenteric arterial stiffness increases significantly (P=0.01) with age (>30 weeks) in KO mice but not in age-matched controls ( Figure 4B ). Pulse-wave velocity (PWV), the rate of propagation of pressure waves within a vessel, is another indirect measurement of vessel aging and an independent cardiovascular risk factor in hypertension. 25 A high PWV indicates lack of elasticity with a fast pulse wave moving along the aorta as measured from carotid to iliac arteries. 26 To control for existing blood pressure differences between WT and KO groups, 6-and 30-week-old RGS5-deficient mice were acutely treated with ATR1 inhibitor before PWV recordings (Online Figure VI) . Figure 4C shows that PWV is significantly enhanced in all KO groups compared with WT and also increased with age (6 weeks: WT 2.3±0.3 vs KO 3.5±0.6 m/s; 30 weeks: WT 2.4±0.5 vs KO 4.4±0.6 m/s; P≤0.0001). Age-related decrease in aortic distensibility likely reflects changes in active arterial tone and structural alterations specific for the vessel wall of RGS5-deficient mice.
Increased Vascular Damage in RGS5-Deficient Hypertensive Mice
Enhanced arterial wall stiffening attributable to changes in extracellular matrix components and growth-mediated wall thickening are important pathological aspects of hypertension. To examine the impact of RGS5 deficiency on renin-angiotensin-mediated hypertension, 2K1C mice were examined. After 4 weeks, blood pressure became elevated in both strains. However, in RGS5 KO mice, blood pressure was increased by 50% compared with WT controls, indicative of an excessive adaptive response (ΔMAP: WT 43.5±5.2 vs KO 86.2±6.1 mm Hg; Figure 5A ). Moreover, medial areas of renal resistance arteries (size 200-300 µm) were significantly enlarged in 2K1C RGS5 KO mice, consistent with medial hypertrophy in more severe hypertension ( Figure 5B; P<0.0001). Chronic hypertension also may lead to perivascular extracellular matrix changes and may contribute to inward remodeling of blood vessels. In kidneys of 2K1C RGS5 KO mice, the area of perivascular fibrosis compared with total vessel area was strongly enhanced in small renal vessels (size 50-70 µm) in the left kidney ( Figure 5C ; P=0.001). Collectively, these findings indicate that loss of RGS5 aggravates hypertension-induced vascular damage.
RGS5 Regulates Blood Pressure Involving PKC, MEK/ERK, and Rho Kinase Signaling Pathways
AngII signaling is predominantly mediated through Gα qdependent pathways, which activate protein kinase C (PKC) and other downstream kinases. 27 Therefore, we first tested whether AngII-induced PKC signaling in hypertension involves RGS5. PKC inhibition with chelerythrine reduced elevated blood pressure in RGS5-deficient mice to levels of those in WT mice (WT untreated 82.6±3.8 vs KO chelerythrine 83.4±5.3 mm Hg). Moreover, chelerythrine abolishes AngII-induced hypertension in RGS5 KO mice (80.3±5.0 mm Hg; Figure 6A ). Thus, MAP after PKC blockade changes more dramatically in KO mice as compared with WT controls (ΔMAP: WT 52.0±4.8 vs KO 80.6±4.4 mm Hg), implying that RGS5 regulates vessel constriction via PKC signaling. This result was confirmed with the PKC inhibitor bisindolylmaleimide I (Online Figure VII) .
AngII signaling also activates the mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway, and loss of RGS5 enhances AngII-stimulated ERK phosphorylation in VSMC because of prolonged Gα q signaling. 28 MEK inhibition with specific inhibitors PD98059 (or U0126; Online Figure VII ) reduces blood pressure in RGS5-deficient mice to WT levels (WT untreated 83.9±3.8 vs KO PD98059 84.0±4.7 mm Hg). PD98059 also abolishes AngII-induced hypertension in RGS5 KO mice (85.7±4.6 mm Hg; Figure 6B ), leading to more dramatic changes in MAP in KO mice than in WT controls (ΔMAP: WT 31.7±2.2 vs KO 76.7±3.4 mm Hg).
Rho-kinase activation is a common feature in hypertension, 29 and chronic infusion with AngII increases Rho kinase activity in arteries. 30 A regulatory role for RGS5 in Rho kinase signaling has not been reported before. Interestingly, Rho kinase-specific inhibitors (HA1077, fasudil hydrochloride, or Y27632; Online Figure VII) reduce AngII-induced hypertension in RGS5 KO mice to normotensive levels of control mice ( Figure 6C ; ΔMAP: WT 28.7±2.1 vs KO 76.9±2.8 mm Hg; P≤0.0001). This is the first evidence demonstrating that RGS5 controls blood pressure homeostasis via Rho kinase signaling. The role of RGS5 in 2 major GPCR signaling pathways involving MEK/ERK and was confirmed in conscious mice chronically infused with AngII and treated with inhibitors (Online Figure VIII) .
RGS5 Differentially Regulates Downstream Signaling of MEK/ERK and Rho Kinase
To further investigate the role of RGS5 in vessel constriction/remodeling involving MEK/ERK and Rho kinase, AngII-induced calcium release was measured with inhibitors. Figure 7A shows that the increase in Fura-2 340/380 nm fluorescence in femoral VSMC induced by March 1, 2013
AngII on a RGS5 KO background is significantly attenuated with MEK inhibition (P=0.05; WT controls; Online Figure  IX) . Interestingly, the AngII-stimulated increases in Fura-2 340/380 nm fluorescence in RGS5 KO VSMC are also reduced with Rho kinase inhibition ( Figure 7B ), which has been shown to regulate G-protein-dependent activation of cellular Ca 2+ entry. 31 Myosin light chain (MLC) is another important regulator of vessel contraction and relaxation and a potential target for MEK and Rho kinase. Signaling through the mitogenactivated protein kinase pathway can activate MLC kinase, 32 which in turn phosphorylates and activates MLC. Rho kinase phosphorylates and inactivates MLC phosphatase, which also results in activation of MLC kinase and MLC. 33 First, we investigated whether MLC activation is enhanced in the absence of RGS5. AngII-induced phosphorylation of MLC is increased in primary VSMCs derived from RGS5 KO mice ( Figure 7C ). Increased Rho kinase activity in the absence of RGS5 also is evident by enhanced phosphorylation of myosin phosphatase target protein 1 at Thr853 (Online Figure  XI) . PD98059 had no significant inhibitory effect on MLC phosphorylation. However, fasudil and bisindolylmaleimide I reduce MLC activation in KO VSMCs to WT levels ( Figure   7C and Online Figure XI) . Consistently, AngII-stimulated ERK phosphorylation is inhibited by PD08056 and bisindolylmaleimide I, but not fasudil (Online Figure XI) . These data show that vessel contraction involving Ca 2+ transients is regulated via MEK/ERK and Rho kinase signaling, whereas MLC activation is predominantly mediated by the Rho kinase pathway. In the absence of RGS5, AngII-induced responses involving both pathways were enhanced, leading to increased vasoconstriction and hypertension; inhibition of key signaling mediators upstream (ATR1) and downstream of RGS5 (PKC, MEK/ERK, or Rho kinase) normalizes blood pressure ( Figure 7D ).
Long-Term Effects of MEK/ERK or Rho Kinase Inhibition in RGS5 Knockout Mice
To analyze whether MEK or Rho kinase inhibition reduces long-term vascular abnormalities, 2K1C mice were treated with PD98059, fasudil, or vehicle 2 weeks after renal constriction for a total of 2 weeks. Consistent with acute results, both inhibitors suppress hypertension induced by chronic renin-angiotensin signaling in RGS5 KO mice to normotensive control levels ( Figure 8A) . Interestingly, MEK/ ERK inhibition abolished hypertrophy in renal arteries, resulting in an 80% reduction of medial thickness in KO mice ( Figure 8B) . In contrast, inhibition of Rho kinase signaling substantially reduced perivascular fibrosis in kidneys with minimal effects on vessel hypertrophy over a 2-week treatment period ( Figure 8C ). Thus, our results indicate that hypertension and increased vascular damage with altered RGS5 signaling can be prevented by blocking cooperative functions of MEK/ERK or Rho kinase signaling.
Discussion
Our study establishes RGS5 as a critical modulator of blood pressure and vascular tone. Endogenous arterial RGS5 levels decrease with chronic AngII stimulation, implying that dynamic regulation of RGS5 represents an adaptive process that controls blood pressure homeostasis. This is strongly supported by our finding that ablation of the RGS5 gene causes hypertension, which is enhanced with physical activity and diurnal factors. Moreover, we demonstrate here that in the absence of RGS5, chronic infusion of the potent vasoconstrictor, AngII, and creation of renal artery stenosis in the 2K1C model exacerbate hypertension. Blockade of ATR1 rapidly abolishes the hypertensive effects. This indicates that hypertension in RGS5 KO mice is likely to be caused by alterations in AngII signaling, thus linking RGS5 to modulation of the renin-angiotensin system. These findings contrast with 2 previous studies that reported that deletion of the RGS5 gene causes hypotension. 21, 22 Here, we demonstrate a hypertensive phenotype in 2 different mouse strains. It is, therefore, unlikely that discrepancies arise because of genetic backgrounds. Furthermore, previous studies measured MAP indirectly using the tail-cuff method and recorded unusually high MAPs of 140 mm Hg for WT controls 21, 22 and 120 mm Hg for hypotensive KO mice. 22 This could be related to the tail-cuff method that can affect blood pressure readings because of heat and restraint stress, which also may render comparisons between experimental groups invalid. 34 In contrast, we used radiotelemetry for continuous direct blood pressure measurements and recorded 115.3±5.1 mm Hg as the day average MAP for RGS5 KO mice, which is clearly hypertensive when compared with physiological readings in WT controls (83.3±2.6 mm Hg). In addition, our study used a variety of complementary analyses, including blood flow and in situ signaling, that reinforced our finding of a hypertensive phenotype. For instance, hypertension in RGS5 KO mice is associated with arterial hypercontractility, resulting in increased peripheral vascular resistance. We also show that AngII induces higher Ca +2 transients in VSMCs isolated from RGS5 KO mice as compared with controls, indicating that RGS5 negatively regulates VSMC contraction. A similar effect has been shown in GPCR-stimulated human airway SMCs In which RGS5 knockdown resulted in higher intracellular Ca +2 levels, which in vivo translates to increased bronchial contractility. 35, 36 Our data also are supported by a recent finding that identified RGS5 as a target for the transcription factor peroxisome proliferator-activated receptor-γ. SMC-specific mutation of peroxisome proliferator-activated receptor-γ results in downregulation of RGS5 and enhanced myogenic tone of resistance arteries. 37 Arteries, like the heart, adapt to hypertension by wall remodeling, a process that includes VSMC hyperplasia or hypertrophy, as well as alterations of extracellular matrix composition. 38 Interestingly, resistance arteries in RGS5deficient mice are stiffer than those in WT controls; differential vascular stiffening is first detectable in femoral arteries (at 6 weeks), followed by mesenteric arteries in aged KO mice (>30 weeks). A reduction in active and passive vascular compliance with aging is consistent with progressive hypertension and increased PWV, as observed in RGS5 KO mice compared with age-matched controls. Defective nitric oxide signaling in RGS5 KO mice also cannot be excluded. Moreover, renovascular complications, such as vessel hypertrophy and perivascular renal fibrosis, are aggravated in RGS5 KO mice. These findings are consistent with RGS5 protecting against cardiac hypertrophy and fibrosis in aortic banding models. 13 RGS5 may even actively regulate transition of VSMC to a more synthetic phenotype under pathological conditions because it previously has been shown to inhibit GPCR-induced hypertrophic responses in cultured VSMC, whereas loss of RGS5 induces hypertrophy. 28 Excessive AngII-mediated contractility and vessel remodeling in the absence of RGS5 are effected by major signaling pathways downstream of ATR1 involving PKC, MEK, and Rho kinase. Speci fic inhibition of PKC, MEK, or Rho kinase signaling in RGS5 KO mice normalizes acute hypertension. AngII-mediated activation of PKC isoforms is classically mediated by Gα q coupling, which is a known target for RGS5 GAP function. 14 PKC activation, in turn, stimulates multiple downstream signaling pathways, including mitogen-activated protein kinase. It previously has been shown that RGS5 inhibits MEK/ERK signaling in vivo, which protects against cardiac hypertrophy. 13 As shown here, RGS5 inhibition of MEK/ERK signaling is equally important to prevent hypertension and may, at least in part, operate through the Gα q -PKC signaling axis. Surprisingly, RGS5 also regulates Rho kinase activity. To our knowledge, this is the first report of an involvement of RGS5 in Rho kinase signaling. RGS5 may be linked to Gα 12/13 by hitherto unrecognized interactions or alternatively regulated Rho kinase via Gα q proteins. Strong evidence exists for Gα 12/13 -independent Gα q -mediated mechanisms of RhoA activation. [39] [40] [41] For instance, a recent report links the RhoA guanine exchange factor, ARHGEF1, with AngII-induced activation of RhoA signaling in VSMCs, which bypasses Gα 12/13 . Instead, AngII activates ARHGEF1 via Gα q and Ca 2+ , involving phosphorylation through janus kinase 2. 42 Interestingly, janus kinase 2 inhibition normalizes blood pressure in RGS5 KO mice and thus could provide a after exposure to AngII and PD98059 as indicated (ratio, n=10-14 for each group; *P<0.05). B, Changes in 340/380 fluorescence recorded as described in (A) after preincubation with 50 μmol/L fasudil followed by stimulation with AngII. Mean of changes in 340/380 fluorescence after exposure to AngII and fasudil as indicated (ratio, n=11-14 for each group; *P<0.05 for all groups). C, Phosphorylation of MLC in femoral VSMC was quantified using incell Western technology (LI-COR Odyssey). Cells were stimulated with 1 μmol/L AngII for 10 minutes with and without PD98059, fasudil, or 10 μmol/L bisindolylmaleimide I (BIM) and fluorescence intensity was quantified (n=3; *P<0.05; **P<0.002; t test; mean±SD). Results are expressed as percentage-relative responses to WT AngII-treated cells, which were set to 100%. Original fluorescence recordings and basal levels of phosphorylated MLC (MLC-P) are shown in Online Figure X . D, RGS5 is a negative regulator of vasoconstriction. In the absence of RGS5 (KO), AngII-mediated constriction is enhanced, leading to higher mean arterial pressure (MAP). Inhibition of AngII receptor 1 (ATR1), protein kinase C, extracellular signal-regulated kinase, and Rho kinase reduces MAP in KO mice to WT basal levels, indicating a regulatory role for RGS5 in these pathways. MYPT-1 indicates myosin phosphatase target protein-1.
link between RGS5 and RhoA/Rho kinase (Online Figure  XII) . Furthermore, our data indicate that MEK/ERK and Rho kinase pathways function most likely independently but cooperatively (eg, Ca 2+ increase) to increase blood pressure in the absence of RGS5. This is consistent with a model in which activation of multiple independent signaling pathways lead to blood pressure changes in response to AngII. Antagonizing one of them is sufficient to normalize blood pressure. Interestingly, hypertension after chronic activation of the renin-angiotensin system in 2K1C mice is also blocked by either MEK/ERK or Rho kinase inhibitors. Morphologically, however, MEK/ERK inhibitors reduce vessel hypertrophy, whereas Rho kinase inhibition ameliorates perivascular fibrosis over a 2-week treatment period, indicating differential effects.
RGS5 is expressed in multiple organs and cell types involved in blood pressure regulation, such as the nervous system, kidney, heart, and VSMC. 5, 8, 43, 44 Although we demonstrate acute and chronic changes in the vascular wall, the relative contribution of the sympathetic nervous system in regulating the hypertensive phenotype needs to be established.
It is becoming evident that the RGS5 molecule is an exquisite and nonredundant modulator of GPCR signaling with emerging clinical implications. For instance, loss of RGS5 has been shown to be crucially involved in cardiac remodeling and heart failure. 13 Reduced RGS5 levels also are implicated in bronchial asthma by promoting airway smooth muscle hyperresponsiveness after prolonged exposure to β 2 -adrenergic receptor agonists. 35, 36 Here, we demonstrate a critical role for RGS5 in hypertension. Importantly, our study establishes a significant, distinct, and causal role of RGS5 in blood pressure and vascular homeostasis. Moreover, we have identified crucial signaling mechanisms by which RGS5 effects are mediated. Supported by genetic linkage studies, 18 our results strongly argue that further mechanistic exploration of RGS5 function will yield critical insights in the pathogenesis and therapy of essential, age-related, and secondary causes of hypertension. 
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